• 

  Scripps Research licenses urine dipstick test for river blindness to IVD Research

  IVD Research Inc., a contract development and manufacturing (CDMO)  firm in Carlsbad, California has licensed a novel biomarker for onchocerciasis—better known as river blindness—from Scripps Research in La Jolla, California. The reagent, developed in the laboratory of Kim Janda, PhD, a professor of chemistry at Scripps Research, will allow clinicians to monitor active infections of onchocerciasis.

• 

  New strategy for cancer therapy spells double trouble for tumors

  "This could give us a way to kill tumors without harming normal cells..."

• 

  AbbVie and Calibr announce collaboration for next generation T-cell therapies

  Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors.

• 

  Two-pronged antibodies draw immune killers directly to cancer cells

  Proteins with a selective targeting system can zero in on a protein found on the surface of several types of cancer cells.

• Calibr’s repurposed drug to treat non-viral diarrhea enters into a clinical trial

  Calibr has now identified and repurposed an FDA-approved drug, clofazimine, used for decades to treat leprosy, as a potential new treatment for cryptosporidiosis.

• 

  Next-generation arthritis treatments could benefit both horses and humans

  More than 27 million people live with osteoarthritis, and it turns out, elite racing and jumping horses do, too.

• TSRI stroke drug demonstrates safety in clinical trial

  "These results lay the groundwork for the next steps toward FDA approval."

• Heroin vaccine blocks lethal overdose

  "The heroin vaccine is one step closer to clinical evaluation," says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.

• 

  Novel regenerative drug for osteoarthritis entering clinical trials

  Known as KA34, the drug is a small molecule that “encourages adult stem cells already residing in the joint to mature toward chondrocytes, the cells that produce and maintain healthy cartilage..."

• Blueprints for anti-cancer drugs discovered in bacterial genomes

  “This points the way toward a new therapeutic opportunity,” says lead investigator Ben Shen.